Dr. Joel Pedro R. Feitosa (pictured), 28, from Rio de Janeiro, Brazil, has been shown as the deceased volunteer in the Brazilian arm of AstraZeneca and in the coronavirus vaccine trial at the University of Oxford.
A Brazilian doctor who died with Covid-19 after volunteering for vaccine trials at AstraZeneca and Oxford University, which is not part of the experimental organization that won the vaccine, reportedly.
Dr. Joel Pedro R. Feitosa, 28, died of headaches from the virus on October 15, confirmed the G1 Rio in Brazil.
Brazilian newspaper Globo and Bloomberg news agency said he was in the organization and won a placebo instead of the control vaccine, which provided resources familiar with the trials.
Dr. Feitosa has been treating patients with Covid-19 since March in emergency rooms and extensive care teams at two hospitals in Rio de Janeiro, Globo said.
He graduated from medical school last year and was in good physical shape before contracting the disease, his circle of family and friends told the newspaper.
Since then, Oxford University has said that the trial will continue after the volunteer’s death, adding that an independent examination did not discover protection problems.
“Following a thorough assessment of this case in Brazil, there was no fear about the protection of the clinical trial and independent review in addition to the Brazilian regulator that the trial should continue,” a university spokesman said in a statement.
The Federal University of Sao Paulo, which coordinates phase 3 trials in Brazil, said an independent review committee also had the continuation of the trial.
“Everything is going according to plan, with no record of severe vaccine-like headaches involving one of the volunteers,” the university said.
The news was that AstraZeneca’s stock turned negative and fell by 1. 7%, but they showed NBC News that the test would continue.
“We cannot comment on individual cases in an ongoing Oxford vaccine trial, as we adhere strictly to medical secrecy and clinical trial regulations, but we can verify that all required review processes have been followed,” he said.
“All medical occasions are thoroughly evaluated through verification researchers, an independent protection oversight committee and regulatory authorities. These evaluations did not raise any considerations for the continuation of the ongoing study. “
Vaccine experts from Oxford and AstraZeneca would possibly be the first to be held as scientists around the global rush to find a cure for Covid-19.
Reports imply that he was not in the organization that won the experimental vaccine and died of COVID-19 headaches on October 15 and parasitic diseases and vaccines in Sao Paulo, Brazil, on July 24.
Oxford and Brazilian fitness authority Anvisa say it will continue and that there are no protection concerns. Photo: AstraZeneca offices in Macclesfield, Cheshire, England, 21 July
Anvisa, the Brazilian physical fitness authority, learned of Dr. Feitosa’s death on October 19, an investigation conducted through the International Security Assessment Committee.
The Gold Institute for Education and Research (IDOR), which is helping to organize the tests in Brazil, said that the independent review “raised no doubts about the protection of the study” and that it will continue. “
The Federal University of Rio de Janeiro, of which Feitosa was a student, issued a condolence on behalf of her friend and friends.
“Joo, I think in this little text, I may not forget how exemplary you were as a doctor and student, but I think the reminiscence I’ll mention to everyone here will be different. I mustn’t forget how smart you are, your boyfriend, brother and friend you were.
The pain in the chest, the vacancy and the preference since your departure accumulates at every moment and what gives us strength at that moment in addition to the affection of so many friends that you have made in life, is what you were.
Covid-19 vaccines would probably not prevent others from getting seriously ill or dying, he said today.
Trials of thousands of volunteers are investigating whether experimental Injections of Covid-19 prevent a user from contracting the infection.
But Professor Peter Doshi, deputy editor of the British Medical Journal, points out that scientists are not waiting to see if volunteers are sick or die if they get it, which would only be the case if the vaccine didn’t work very well. – prior to deployment.
This is a specific fear for older adults, who are at peak risk of serious consequences of Covid-19, as the vaccine would possibly not be as effective at protecting them from coronavirus capture in the first place.
Vaccines look just as good for others over age 60 because they have an ancient immune system.
Professor Doshi of the University of Maryland also revealed that studies will not result in transmission among others slowing down. Scientists do not measure whether the contracters pass it on to their friends and family, whether they themselves are in poor health or not.
None of the pioneers (Moderna, Pfizer, AstraZeneca, Janssen, Sinopharm or Sinovac) can see if their vaccines will save lives in their latest trials.
But in reaction to Professor Doshi’s article, scientists say there are “excellent reasons” to conduct the trials, the main of which is to encourage the search for a vaccine that, in a different way, can take years because very few Covid-19 patients become seriously ill.
Comments below have been moderated.
By posting your comment, you settle for our internal rules.
We will post your comment and link to the story in your Facebook timeline at the same time as it will be posted on MailOnline. To do this, we will link your MailOnline account to your Facebook account. We’ll ask you to verify this for your first Facebook post.
You can in each post if you need it posted to Facebook. Your main Facebook points will be used to provide you with personalized content, marketing and advertising in accordance with our privacy policy.
Edited through Associated Newspapers Ltd
Part of the Daily Mail, The Mail on Sunday and Metro Media Group